Alethio Therapeutics
Alethio Therapeutics is developing next-generation, disease-modifying biologic therapies for myeloproliferative neoplasms (MPNs), a group of chronic blood cancers that remain largely incurable. Its lead program, ATX-011, is a first-in-class monoclonal antibody targeting the G6B antigen uniquely overexpressed on mutant MPN clones, validated across samples from more than 100 patients.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
Funding
Raised to date
$90MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
across 1 round
OS
UO$90M · Series A
Announced Nov 2026 · from article date
Disclosed cumulative: $90M
Founders
Founder details are not available yet.
Product
Problem
Approximately 300,000 people in the US live with myeloproliferative neoplasms (MPNs), a group of chronic blood cancers that remain largely incurable. Current treatments can ease symptoms but do not modify the course of the disease, leaving patients with pain, fatigue, and limited life expectancy.
Solution
Alethio Therapeutics is developing next-generation, disease-modifying therapies designed to improve outcomes for patients with MPNs. The company's lead program, ATX-011, is a first-in-class monoclonal antibody targeting G6B, a novel antigen uniquely overexpressed on the mutant MPN clone. This target has been validated across samples from more than 100 MPN patients. Alongside ATX-011, Alethio is developing a program targeting mutant calreticulin (CALR)-driven disease, which occurs in roughly 30% of MPN patients. The company's pipeline is powered by its proprietary ARTEMIS Engine, which supports the discovery and development of novel biologic therapies aimed at changing the course of these diseases.
Target Audience
Primary customers are patients with myeloproliferative neoplasms and the hematologist-oncologists who treat them, as well as clinical research partners evaluating novel disease-modifying therapies.
Features
- Lead program ATX-011: first-in-class monoclonal antibody targeting G6B, an antigen uniquely overexpressed on the mutant MPN clone
- Target validation across samples from more than 100 MPN patients
- Second program targeting mutant calreticulin (CALR)-driven disease, relevant to approximately 30% of MPN patients
- Proprietary ARTEMIS Engine platform supporting discovery and development of novel biologic disease-modifying therapies
- Focus on disease modification rather than symptom management alone